Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study

Aims To assess the non‐inferiority of MYL‐1501D, a proposed biosimilar or follow‐on biological agent to marketed insulin glargine, to reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, New Jersey) based on change in glycated hemoglobin (HbA1c). Materials and methods INSTRIDE 2...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2019-01, Vol.21 (1), p.129-135
Hauptverfasser:	Blevins, Thomas C., Barve, Abhijit, Sun, Bin, Raiter, Yaron, Aubonnet, Patrick, Muniz, Rafael, Athalye, Sandeep, Ankersen, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics biosimilar Blood glucose Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) efficacy Hemoglobin Hypoglycemia Immunogenicity Insulin insulin glargine Patients Safety type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!